23876 Federal Register / Vol. 87, No. 77 / Thursday, April 21, 2022 / Notices 

doi.org/10.1016/j.japh.2020.01.004. 

32. Buffington, D.E., A. Lozicki, T. Alfieri, et 

al. ‘‘Understanding Factors That 

Contribute to the Disposal of Unused 

Opioid Medication.’’ Journal of Pain 

Research, Vol. 12 (February 2019): 725– 

732. https://doi.org/10.2147/jpr.s171742. 

33. Walmart. ‘‘Stewardship.’’ https://

corporate.walmart.com/stewardship. 

Accessed October 31, 2021. 

34. Rite Aid. ‘‘Rite Aid Makes Free Opioid 

Disposal Solution Available At More 

Than 2,500 Pharmacies Nationwide.’’ 

https://www.businesswire.com/news/

home/20180521005532/en/. Accessed 

October 31, 2021. 

35. CVS. ‘‘CVS Pharmacy to Offer Safe 

Medication Disposal Chain-Wide in 

2020.’’ https://cvshealth.com/news-andinsights/press-releases/cvs-pharmacy-tooffer-safe-medication-disposal-chainwide-in-2020. Accessed November 1, 

2021. 

36. Walgreens. ‘‘Safe Medication Disposal— 

Dispose of Unused Medication.’’ https:// 

www.walgreens.com/topic/pharmacy/

safe-medication-disposal.jsp. Accessed 

November 1, 2021. 

37. Kroger. ‘‘National Drug Take-back Day’’ 

https://www.kroger.com/health/

pharmacy/prescriptions/takeback. 

Accessed November 3, 2021. 

38. Drug Take Back, Consolidated Laws of 

New York Chapter 45 Article 2–B, 

available at https://www.nysenate.gov/

legislation/laws/PBH/A2-B. 

39. Drug Take-Back Program, Revised Code of 

Washington 69.48, available at https://

app.leg.wa.gov/rcw/default.aspx?

cite=69.48. 

40. Pharmaceutical and Sharps Waste 

Stewardship Program, California Code of 

Regulations Title 14, Chapter 11, Div. 7, 

Art. 4, available at https://

govt.westlaw.com/calregs/Browse/Home/

California/CaliforniaCodeofRegulations?

guid=I3A11525A8CDD4A6E87920B

BB389851C4&origination

Context=documenttoc&transitionType=

Default&contextData=(sc.Default). 

41. Hwang, C.S., E.M. Kang, Y. Ding, et al. 

‘‘Patterns of Immediate-Release and 

Extended-Release Opioid Analgesic Use 

in the Management of Chronic Pain, 

2003–2014.’’ JAMA Network Open, Vol. 

1(2) (June 2018): e180216. https://

jamanetwork.com/journals/

jamanetworkopen/fullarticle/2682877. 

42. Kennedy-Hendricks, A., A. Gielen, E. 

McDonald, et al. ‘‘Medication Sharing, 

Storage, and Disposal Practices for 

Opioid Medications Among US Adults.’’ 

JAMA Internal Medicine, Vol. 176(7) 

(July 2016): 1027–1029. https://

jamanetwork.com/journals/

jamainternalmedicine/fullarticle/

2527388. 

43. Neill, L.A., H.S. Kim, K.A. Cameron, et 

al. ‘‘Who Is Keeping Their Unused 

Opioids and Why?’’ Pain Medicine, Vol. 

21(1) (January 2020): 84–91. https://

academic.oup.com/painmedicine/

article/21/1/84/5418890. 

44. * FDA. ‘‘Safe Opioid Disposal—Remove 

the Risk Outreach Toolkit.’’ https://

www.fda.gov/drugs/safe-disposalmedicines/safe-opioid-disposal-removerisk-outreach-toolkit. Accessed 

November 23, 2021. 

Dated: April 13, 2022. 

Lauren K. Roth, 

Associate Commissioner for Policy. 

[FR Doc. 2022–08372 Filed 4–20–22; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Dental & 

Craniofacial Research; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Dental and Craniofacial Research Special 

Emphasis Panel; Summer Research 

Education R25 and DSR Member Conflict 

SEP. 

Date: June 17, 2022. 

Time: 11:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Dental & 

Craniofacial Research, 6701 Democracy 

Blvd., Bethesda, MD 20817 (Virtual Meeting). 

Contact Person: Aiwu Cheng, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Activities 

National Institute of Dental & Craniofacial 

Research, National Institutes of Health, 6701 

Democracy Blvd., Bethesda, MD 20892, 

Aiwu.cheng@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.121, Oral Diseases and 

Disorders Research, National Institutes of 

Health, HHS) 

Dated: April 18, 2022. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–08522 Filed 4–20–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Health 

Services Organization, Delivery, Quality and 

Effectiveness. 

Date: May 4, 2022. 

Time: 11:00 a.m. to 1:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Wenjuan Wang, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3154, 

Bethesda, MD 20892, (301) 480–8667, 

wangw22@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: April 15, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–08500 Filed 4–20–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 


jspears on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 87, No. 77 / Thursday, April 21, 2022 / Notices 23877 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Bioengineering 

Sciences & Technologies Integrated Review 

Group; Biodata Management and Analysis 

Study Section. 

Date: June 2–3, 2022. 

Time: 9:00 a.m. to 8:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: E. Bryan Crenshaw, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 480–7129, bryan.crenshaw@

nih.gov. 

Name of Committee: Risk, Prevention and 

Health Behavior Integrated Review Group; 

Psychosocial Development, Risk and 

Prevention Study Section. 

Date: June 2–3, 2022. 

Time: 9:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Anna L. Riley, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3114, 

MSC 7759, Bethesda, MD 20892, 301–435– 

2889 rileyann@csr.nih.gov. 

Name of Committee: Cell Biology 

Integrated Review Group; Biology and 

Development of the Eye Study Section. 

Date: June 2–3, 2022. 

Time: 10:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Kevin Czaplinski, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, 6701 Rockledge Drive, 

Bethesda, MD 20892, (301) 480–9139, 

czaplinskik2@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: April 15, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–08501 Filed 4–20–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Dental & 

Craniofacial Research; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: NIDCR Special Grants 

Review Committee. 

Date: June 23–24, 2022. 

Time: 9:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Dental & 

Craniofacial Research, 6701 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Contact Person: Nisan Bhattacharyya, 

Ph.D., Scientific Review Officer, Scientific 

Review Branch, National Institute of Dental 

& Craniofacial Research, National Institutes 

of Health, 6701 Democracy Boulevard, Suite 

668, Bethesda, MD 20892, 301–451–2405, 

nisan.bhattacharyya@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.121, Oral Diseases and 

Disorders Research, National Institutes of 

Health, HHS) 

Dated: April 18, 2022. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–08521 Filed 4–20–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Notice of Meeting 

Pursuant to Public Law 92–463, 

notice is hereby given that the 

Substance Abuse and Mental Health 

Services Administration’s (SAMHSA) 

Center for Substance Abuse Prevention’s 

(CSAP) Drug Testing Advisory Board 

(DTAB) will convene via web 

conference on June 21st, 2022, from 

10:00 a.m. EDT to 4:30 p.m. EDT, and 

June 22nd, 2022, from 10:00 a.m. EDT 

to 1:00 p.m. EDT. 

The board will meet in open-session 

June 21st, 2022, from 10:00 a.m. EDT to 

2:15 p.m. EDT to discuss the Mandatory 

Guidelines for Federal Workplace Drug 

Testing Programs, updates on the Drug 

Free Workplace Program as well as 

updates from the Department of 

Transportation, the Nuclear Regulatory 

Commission, a presentation by Dr. Barry 

Sample on Workforce Drug Testing for 

Marijuana in 2021, and a presentation 

by Dr. Svante Vikingsson on Hydroxy 

Cocaine and Cocaine Ratios in Hair. 

The board will meet in closed-session 

on June 21st, 2022, from 2:45 p.m. EDT 

to 4:30 p.m. EDT and June 22nd, 2022, 

from 10:00 a.m. EDT to 1:00 p.m. EDT, 

to discuss confidential issues 

surrounding the proposed Mandatory 

Guidelines for Federal Workplace Drug 

Testing Programs (hair), preliminary 

and unpublished studies on hydroxy 

cocaine and cocaine ratios in hair, 

studies on quantitative agreement in 

hair labs, and oral fluid topical solution 

data from the Johns Hopkins University 

Behavioral Pharmacology Research Unit 

(BPRU). Therefore, the June 21st, 2022, 

from 2:45 to 4:30 and June 22nd, 2022, 

from 10:00 a.m. EDT to 1:00 p.m. EDT 

meetings are closed to the public, as 

determined by the Assistant Secretary 

for Mental Health and Substance Use, 

SAMHSA, in accordance with 5 U.S.C. 

552b(c)(4) and (9)(B), and 5 U.S.C. App. 

2, Section 10(d). 

Meeting registration information can 

be completed at http://

snacregister.samhsa.gov/ 

MeetingList.aspx. Web conference and 

call information will be sent after 

completing registration. Meeting 

information and a roster of DTAB 

members may be obtained by accessing 

the SAMHSA Advisory Committees 

website, https://www.samhsa.gov/ 

about-us/advisory-councils/meetings or 

by contacting the Designated Federal 

Officer, Lisa Davis. 


jspears on DSK121TN23PROD with NOTICES1